804 related articles for article (PubMed ID: 31158948)
1. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z
Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948
[TBL] [Abstract][Full Text] [Related]
2. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
[TBL] [Abstract][Full Text] [Related]
3. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis.
Zhang Z; Zhou Y; Yang J; Hu K; Huang Y
BMC Cancer; 2019 May; 19(1):511. PubMed ID: 31142283
[TBL] [Abstract][Full Text] [Related]
5. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis.
Gu L; Yao Q; Shen Z; He Y; Ng DM; Yang T; Chen B; Chen P; Mao F; Yu Q
J Gastroenterol Hepatol; 2020 Sep; 35(9):1467-1476. PubMed ID: 32180249
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis.
Chen MB; Wang H; Zheng QH; Zheng XW; Fan JN; Ding YL; Niu JL
PLoS One; 2019; 14(11):e0224773. PubMed ID: 31751366
[TBL] [Abstract][Full Text] [Related]
7. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
Tseng CH; Tseng CM; Wu JL; Hsu YC; El-Serag HB
J Gastroenterol Hepatol; 2020 Oct; 35(10):1684-1693. PubMed ID: 32343431
[TBL] [Abstract][Full Text] [Related]
8. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and cost-effectiveness of antiviral regimens for entecavir-resistant hepatitis B: A systematic review and network meta-analysis.
Yang SS; Cai CW; Ma XQ; Xu J; Yu CB
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):507-514. PubMed ID: 33051132
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis.
Dave S; Park S; Murad MH; Barnard A; Prokop L; Adams LA; Singh S; Loomba R
Hepatology; 2021 Jan; 73(1):68-78. PubMed ID: 32277491
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
Jung SK; Kim KA; Ha SY; Lee HK; Kim YD; Lee BH; Paik WH; Kim JW; Bae WK; Kim NH; Lee JS; Jwa YJ
Clin Mol Hepatol; 2015 Mar; 21(1):41-8. PubMed ID: 25834801
[TBL] [Abstract][Full Text] [Related]
12. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.
Yuan BH; Li RH; Huo RR; Li MJ; Papatheodoridis G; Zhong JH
J Gastroenterol Hepatol; 2022 May; 37(5):782-794. PubMed ID: 35080052
[TBL] [Abstract][Full Text] [Related]
13. Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients.
Wang HM; Hung CH; Lee CM; Lu SN; Wang JH; Yen YH; Kee KM; Chang KC; Tseng PL; Hu TH; Chen CH
J Gastroenterol Hepatol; 2016 Jul; 31(7):1307-14. PubMed ID: 26758501
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis.
Ha I; Chung JW; Jang ES; Jeong SH; Kim JW
J Gastroenterol Hepatol; 2020 Oct; 35(10):1774-1781. PubMed ID: 32154938
[TBL] [Abstract][Full Text] [Related]
15. Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B.
Kim YM; Shin HP; Lee JI; Joo KR; Cha JM; Jeon JW; Yoon JY; Kwak MS
Saudi J Gastroenterol; 2018; 24(6):326-335. PubMed ID: 30004042
[TBL] [Abstract][Full Text] [Related]
16. Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan.
Hu TH; Yueh-Hsia Chiu S; Tseng PL; Chen CH; Lu SN; Wang JH; Hung CH; Kee KM; Lin MT; Chang KC; Lin MC; Chien RN
Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1695-1706. PubMed ID: 33111400
[TBL] [Abstract][Full Text] [Related]
17. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A protocol for systematic review and meta-analysis.
Chen MB; Wang H; Zheng QH; Zheng XW; Fan JN; Ding YL; Yue MX
Medicine (Baltimore); 2019 Aug; 98(34):e16943. PubMed ID: 31441888
[TBL] [Abstract][Full Text] [Related]
19. Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
Shin JW; Jeong J; Jung SW; Lee SB; Park BR; Kim MJ; Park EJ; Park NH
Dig Dis Sci; 2021 May; 66(5):1739-1750. PubMed ID: 32524416
[TBL] [Abstract][Full Text] [Related]
20. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
